CTOs on the Move

Kyruus Health

www.kyruushealth.com

 
As the industry`s largest care access platform Kyruus Health enables our partners to efficiently guide and match people to the care that`s right for them. We create connections across the entire healthcare ecosystem so that every stakeholder can access and harness the most accurate, comprehensive, and contextually relevant information. By enabling informed decisions and confident action, we support healthier outcomes, reduce friction in healthcare, and grant more time back in everyone`s day. At the heart of care access, we connect people to healthcare in a whole new way.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details
Harshit Shah
Chief Technology Officer Profile

Similar Companies

Verim Research

Verim Research is a Hood River, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Solace Pediatric Healthcare

Solace Pediatric Healthcare is a leading provider of pediatric occupational, physical, speech and feeding therapy services in the state of Colorado. They offer in-home and telehealth therapy services for infants and children with developmental delays o...

NM Dept. of Health

The mission of New Mexico Department of Health is to promote health and wellness, improve health outcomes, and assure safety net services for all people in New Mexico.

Healthline.com

Healthline.com is a Adrian, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract). Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world`s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter`s lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.